Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal.

Silva Miguel L, Silva Miguel N, Inês M.

Cost Eff Resour Alloc. 2013 Apr 12;11(1):8. doi: 10.1186/1478-7547-11-8.

2.

Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.

Bereza BG, Machado M, Einarson TR.

Clin Ther. 2009 Jun;31(6):1279-308. doi: 10.1016/j.clinthera.2009.06.004. Review.

PMID:
19695395
3.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
4.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

5.

A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder.

Allgulander C, Nutt D, Detke M, Erickson J, Spann M, Walker D, Ball S, Russell J.

J Psychopharmacol. 2008 Jun;22(4):417-25. doi: 10.1177/0269881108091588.

PMID:
18635722
7.

Long-term treatment strategies in anxiety disorders.

Allgulander C, Hirschfeld RM, Nutt DJ.

Psychopharmacol Bull. 2002 Summer;36 Suppl 2:79-92. Review.

PMID:
12490824
8.

Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.

Sheehan DV.

J Clin Psychiatry. 2001;62 Suppl 19:26-31. Review.

PMID:
11577788
9.

Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder.

Sheehan DV.

J Clin Psychiatry. 1999;60 Suppl 22:23-8. Review.

PMID:
10634352
10.

A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.

Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A, Moore D.

Health Technol Assess. 2006 Jun;10(20):iii-iv, ix-113. Review.

11.

[Cost-effectiveness of venlafaxine for the treatment of depression and anxiety. Bibliographic review].

Baca Baldomero E, Rubio-Terrés C.

Actas Esp Psiquiatr. 2006 May-Jun;34(3):193-201. Review. Spanish.

PMID:
16736393
12.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

13.

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.

14.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

15.

WCA recommendations for the long-term treatment of generalized anxiety disorder.

Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP; World Council of Anxiety.

CNS Spectr. 2003 Aug;8(8 Suppl 1):53-61. Review.

PMID:
14767398
16.

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS.

Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv. Review.

17.

Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.

Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D.

Health Technol Assess. 2010 Jun;14(31):iii-iv, 1-75. doi: 10.3310/hta14310. Review.

Items per page

Supplemental Content

Write to the Help Desk